CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $267.23M, lower than 95% of all stocks globally
- PositionGross margin is 86.8%, higher than 95% of its Medical Devices peers (median 61.5%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
267.23MUSDvs all stocks (USD)
Revenue (TTM)
45.08MUSDvs all stocks (USD)
Profit Margin
-62.59%vs Medical Devices peers
Beta
0.4380xvs all stocks
52-Week Change
-6.96%vs all stocks
Market Capitalization
267.23MUSDvs all stocks (USD)
Enterprise Value
255.37MUSDvs all stocks (USD)
Forward P/E
-17.36xvs Medical Devices peers
Price to Sales (TTM)
5.93xvs Medical Devices peers
Price to Book (MRQ)
40.56xvs Medical Devices peers
Enterprise to Revenue
5.67xvs Medical Devices peers
Enterprise to EBITDA
-8.53xvs Medical Devices peers
Gross Margin
86.78%vs Medical Devices peers
Profit Margin
-62.59%vs Medical Devices peers
Operating Margin
-86.03%vs Medical Devices peers
Return on Assets (TTM)
-36.75%vs Medical Devices peers
Return on Equity (TTM)
205.81%vs Medical Devices peers
Revenue (TTM)
45.08MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.9010USDUpdated Sep 28, 2026Quarterly Revenue Growth
1.70%vs Medical Devices peers
Gross Profit (TTM)
38.67MUSDvs all stocks (USD)
EBITDA (TTM)
-29.95MUSDvs all stocks (USD)
Net Income (TTM)
-57.25MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
1.73%vs Medical Devices peers
Operating Cash Flow (TTM)
-22.80MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-10.88MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
45.15MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
6.96MUSDFY2025 · Dec 31, 2025Gross Profit
38.19MUSDFY2025 · Dec 31, 2025Operating Income
-26.95MUSDvs all stocks (USD)
Pre-tax Income
-39.22MUSDFY2025 · Dec 31, 2025Income Tax Expense
7.00KUSDFY2025 · Dec 31, 2025Net Income
-39.23MUSDFY2025 · Dec 31, 2025EBIT
-33.68MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-26.22MUSDFY2025 · Dec 31, 2025Research & Development
14.96MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
50.17MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
555.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
5.54MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-39.23MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
30.46MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-25.25MUSDFY2025 · Dec 31, 2025Free Cash Flow
-26.08MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
20.79MUSDFY2025 · Dec 31, 2025Income Tax Paid
16.00KUSDFY2025 · Dec 31, 2025Interest Paid
3.70MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-39.23MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
626.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
9.13MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.02MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.63MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
837.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-838.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-838.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
10.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-81.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-2.07MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
29.85MUSDFY2025 · Dec 31, 2025Shares Outstanding
61.47MSharesUpdated Sep 28, 2026Float Shares
49.50MSharesUpdated Sep 28, 2026Shares Short
3.35MSharesUpdated Sep 28, 2026Short Ratio
30.32daysvs all stocks
Short % of Shares Outstanding
7.17%vs all stocks
% Held by Insiders
33.96%vs all stocks
% Held by Institutions
35.72%vs all stocks
Total Cash (MRQ)
46.29MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7520USDUpdated Sep 28, 2026Total Debt (MRQ)
34.43MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
5.26xvs Medical Devices peers
Current Ratio (MRQ)
5.35xvs Medical Devices peers
Book Value per Share (MRQ)
0.1070USDUpdated Sep 28, 2026Total Assets
35.33MUSDvs all stocks (USD)
Total Current Assets
32.24MUSDFY2025 · Dec 31, 2025Total Liabilities
69.19MUSDFY2025 · Dec 31, 2025Total Non-current Assets
3.09MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
57.69MUSDFY2025 · Dec 31, 2025Total Current Liabilities
11.50MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
20.44MUSDFY2025 · Dec 31, 2025Accounts Receivable
6.56MUSDFY2025 · Dec 31, 2025Inventory
3.08MUSDFY2025 · Dec 31, 2025Accounts Payable
3.00MUSDFY2025 · Dec 31, 2025Short-term Debt
167.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
234.00KUSDFY2025 · Dec 31, 2025Long-term Debt
34.27MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
23.42MUSDFY2025 · Dec 31, 2025Common Stock (Book)
4.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-330.58MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-33.86MUSDvs all stocks (USD)
52-Week Low
2.20USDUpdated Sep 28, 202652-Week High
7.95USDUpdated Sep 28, 202652-Week Change
-6.96%vs all stocks
Beta
0.4380xvs all stocks
50-Day MA
4.89USDUpdated Sep 28, 2026200-Day MA
4.76USDUpdated Sep 28, 2026Avg 10-Day Volume
766.89KSharesUpdated Sep 28, 2026Avg 30-Day Volume
327.87KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-1.33USDUpdated Sep 28, 2026Other Income / Expense
-7.29MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 86.8%, higher than 95% of its Medical Devices peers (median 61.5%)Significant
Gross margin: 0.87Industry median: 0.62Industry P95: 0.85Peers compared: 102
Operating margin is -86%, lower than 95% of its Medical Devices peers (median 7.3%)Significant
Operating margin: -0.86Industry median: 0.07Industry P5: -0.73Peers compared: 102
Return on equity is 205.8%, higher than 95% of its Medical Devices peers (median 2.5%)Significant
Return on equity: 2.06Industry median: 0.03Industry P95: 0.17Peers compared: 102
Debt-to-equity is 5.26×, higher than 95% of its Medical Devices peers (median 0.11×)Significant
Debt-to-equity: 5.26Industry median: 0.11Industry P95: 1.28Peers compared: 102
Price-to-book is 40.56×, higher than 95% of its Medical Devices peers (median 2.51×)Significant
Price-to-book: 40.56Industry median: 2.51Industry P95: 12.98Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.87Profit Margin: -0.63
Significant cash reserves alongside high leverageNotable
Cash (USD): 46,288,000Total Debt (USD): 34,426,000Debt-to-Equity: 5.26
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $267.23M, lower than 95% of all stocks globallySignificant
Market cap (USD): 267,233,764Global P5: 275,556,405.438
Companies that share the same coordination system — how they create, deliver, or capture value.
Greenwich LifeSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ginwa Enterprise Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hunan Nucien Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Lexeo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Northwest Biotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Oryzon Genomics S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Lineage Cell Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tanvex Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cresco Labs Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Triveni Engineering & Industries Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Kangxin New Materials Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Hyosung Heavy Industries Corporation
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated